Working with bacteriophages and nematodes, the University of California, Berkeley, molecular biologist uncovered a role for genetic switches in early development.
Switch Master: A Profile of Barbara Meyer
Switch Master: A Profile of Barbara Meyer
Working with bacteriophages and nematodes, the University of California, Berkeley, molecular biologist uncovered a role for genetic switches in early development.
Working with bacteriophages and nematodes, the University of California, Berkeley, molecular biologist uncovered a role for genetic switches in early development.
Working with bacteriophages and nematodes, the University of California, Berkeley, molecular biologist uncovered a role for genetic switches in early development.
Neil S. Greenspan and Arturo Casadevall | Nov 1, 2019 | 3 min read
Metabolic disrupters, phages, and other approaches are going to be needed to treat the broadest possible range of patients infected by bacterial pathogens resistant to multiple drugs.
In Chapter 3, “The Enemy of Our Enemy Is Our Friend: Infecting the Infection,” author Emily Monosson makes the case for bacteriophage therapy in the treatment of infectious disease.
When engineered to use a four-billion-year-old version of the protein thioredoxin, the bacteria can stall bacteriophage replication, a new study shows.
In bacteriophage genomes, researchers find three anti-CRISPR proteins that naturally inhibit CRISPR-Cas9 in one bacterial species and can do the same in human cells.
In the DNA of the WO phage, which infects arthropod-inhabiting Wolbachia, researchers find sequences related to a black widow spider’s toxin and other animal genes.
Phage therapy to combat bacterial infections is garnering attention for the second time in 100 years, but solid clinical support for its widespread use is still lacking.